GlassScriptPhysician profile
Christopher M Lynch
NPI 1992809164
$2,156.62
in general payments reported to CMS, 2019-2025
28 companies · $531 in 2025
The $531 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $160 · 2021: $474 · 2022: $312 · 2023: $101 · 2024: $391 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.01 | 2019-2022 | |
| Biogen, INC. | $215.25 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $204.56 | 2020-2022 | |
| Astellas Pharma US INC | $155.72 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $148.03 | 2025 | |
| Mayne Pharma Commercial LLC | $85.48 | 2023-2025 | |
| Organon LLC | $82.34 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $73.50 | 2022-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Agile Therapeutics, INC. | $61.82 | 2021-2022 | |
| Exeltis, USA INC. | $61.45 | 2019-2022 | |
| Coopersurgical, INC. | $57.23 | 2024-2025 | Sos, Fisherbrand Disposable Liquid Infant Heel Warmer, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $56.10 | 2022-2024 | |
| Intuitive Surgical, INC. | $56.02 | 2024-2025 | |
| Therapeuticsmd, INC. | $52.82 | 2019-2022 | |
| Avion Pharmaceuticals | $39.17 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.84 | 2019-2020 | |
| Millicent US INC | $33.35 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Evofem Biosciences, INC. | $29.26 | 2021 | |
| Pharmacosmos Therapeutics INC. | $29.21 | 2024-2025 | Monoferric |
| Ferring Pharmaceuticals INC. | $21.97 | 2024 | Euflexxa |
| Mylan Pharmaceuticals INC. | $18.64 | 2021 | |
| Covidien LP | $17.14 | 2019 | |
| Olympus America INC. | $15.56 | 2023 | Endoeye Flex Deflectable Videoscope |
| Baxter Healthcare | $14.93 | 2023 | Perclot |
| Merck Sharp & Dohme LLC | $14.44 | 2024 | Gardasil 9, Gardasil |
| Channel Medsystems, INC. | $14.25 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.15 | 2019 | |
| Currax Pharmaceuticals LLC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.